IHUMAN INC
IHNYSETrading Snapshot
- Day Range
- $1.16 – $1.18
- 52-Week Range
- $1.11 – $3.09
- Volume
- $2.32B
- Avg Volume
- $2.49B
- Shares Outstanding
- 10.2M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $807M
- Last Q Revenue
- $182M
- P/E Ratio
- 1.1
- P/S Ratio
- 0.1x
- EPS (TTM)
- $7.18
- Dividend Yield
- 7.39%
- Dilution (1yr)
- −1.2%
Why Investors Own IH
- ✓High-growth profile — revenue up +15.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
IHUMAN INC
IH
StockOtter · stockotter.spaceAbout IHUMAN INC
Operating within the People's Republic of China, iHuman Inc. specializes in delivering educational resources aimed at fostering cognitive growth. Their offerings reach a broad audience, encompassing individual consumers, early learning institutions, and wholesale distributors. A significant portion of their portfolio consists of interactive and self-guided digital applications. These include popular titles such as iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, and iHuman Readers. Beyond digital platforms, iHuman Inc. also furnishes a diverse array of physical educational content, ranging from books and interactive tools to smart devices. These resources are specifically designed to cultivate essential childhood skills, such as verbal communication, analytical reasoning, autonomous reading, and creative expression. Established in 1996, the company maintains its headquarters in Beijing, located within the People's Republic of China.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
iHuman Inc. Announces Second Quarter 2026 Unaudited Financial Results
BEIJING, Sept. 29, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered knowledge and personal growth products, today announced its unaudited financial results for t
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Takeda (TSE:4502/NYSE: TAK) announced that the [url="]New England Journal of Medicine[/url] published results from two Phase 3 studies evaluating oveporexton (OR
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Takeda ([url="]TOKYO:4502/NYSE: TAK[/url]) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) f